A/Prof Colman Taylor is a health economics, healthcare reimbursement and policy expert with experience across government, industry and academia. He contributes to health economics and health technology assessment through advisory, policy and academic roles. He is a trusted advisor to industry associations and an advocate for patient access.

Strategic Leadership

A/Prof Colman Taylor joined HTANALYSTS in 2014 and participated in the 2016 management buy-out that helped positioned the firm as a leader in health technology assessment and healthcare consultancy. Since then, he has provided strategic oversight for more than 500 projects across Australia and the Asia Pacific.   Importantly, he has personally contributed to more than 100 reimbursement submissions and economic models, securing funding for transformative therapies and technologies.

In particular, Colman specialises in health technology assessment to support reimbursement, policy reform and funding decisions. His work spans pharmaceuticals, medical technology and digital health.

Policy and Industry Engagement

In addition, Colman serves as a strategic advisor to leading industry associations, including Medicines Australia, the Medical Technology Association of Australia (MTAA), and Pathology Technology Australia (PTA). As a previous board member of the Australian Genomics Coalition, he is dedicated to advancing precision medicine and equitable access to genomics.

Throughout his career, Colman has played a pivotal role in shaping health policy and HTA reform, co-leading reports presented in Parliament House and contributing to innovative models of healthcare funding.

Academic Leadership

In academia, Colman leads the Health Economics Program at The George Institute and is a Conjoint Associate Professor at UNSW. His research focuses on health economics in critical care, social impact assessment and policy-driven evaluation. He has authored more than 50 peer-reviewed publications and secured over $18 million in research funding.  He has contributed to impactful initiatives such as the inaugural HTA Summit and national health economic guidelines.

Impact and Collaboration

More broadly, Colman is recognised for his expertise in health technology assessment. His work supports evidence-based funding and policy decisions across healthcare systems. Beyond research, he has helped create pathways for subsidised access to advanced treatments and influenced HTA reform.

In addition, Colman mentors emerging leaders in health economics. As Past President of the Australian ISPOR Committee, he continues to strengthen collaboration between academia, industry and government to improve patient access and value-based healthcare across the region.